Companies · Listed company · 🇮🇳

MphasiS Limited

MPHASIS · NSE · ₹2,297 a share (close of 05 Oct 2026)

Available company data, source links and archived checks for MphasiS Limited. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.

Revenue rose 17.5%; Net profit was ₹489.51 crore.

Quarter ended 2026-06-30 · consolidated · Company filing

Recorded quarterly figures
QuarterRevenue / incomeYoY ProfitYoYNet marginSource
Jun 2026Revenue: ₹4,384 cr+17.5%Net profit: ₹490 cr+10.8%11.2%Company filing source
Mar 2026Revenue: ₹4,243 cr+14.4%Net profit: ₹510 cr+14.1%12.0%Company filing source
Dec 2025Revenue: ₹4,003 cr—Net profit: ₹442 cr—11.0%Company filing source
Sep 2025Revenue: ₹3,902 cr—Net profit: ₹469 cr—12.0%Company filing source
Jun 2025Revenue: ₹3,732 cr+9.1%Net profit: ₹442 cr+9.2%11.8%Company filing source
Mar 2025Revenue: ₹3,710 cr—Net profit: ₹446 cr—12.0%Company filing source

YoY means change from the same quarter a year earlier. — means no comparable figure is available. Older entries with incomplete source details have not been revalidated under the current checks.

Recently checked facts

A grantee who is a USA employee subject to the U.S. Internal Revenue Code is subject to Automatic Exercise.

✓ verified by reading the document archived check · 2026-10-05 exchange filing →

Automatic Exercise applies under the RSU Plan 2021, with shares arising from vested units settled by the Mphasis Employees Benefit Trust to employees upon vesting.

✓ verified by reading the document archived check · 2026-10-05 exchange filing →

BSE Limited

The Manager, Listing

National Stock Exchange of India Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

Scrip Code: 526299

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Cancellation and grant of stock options

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of the provisions of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ( ' SEBI Regulations ' ), we wish to inform that the ESOP Compensation Committee vide resolutions passed on 7 September 2026 approved the following:

1. Cancellation of grant of 4, 15,060 Employee Stock Options (' Options ') option under the Employee Stock Option Plan 2016 (ESOP 2016) and 92,400 Restricted Stock Units (' RSUs ') under the Restricted Stock Units Plan 2021 (RSU Plan 2021)

The Company vide its letter dated 21 August 2026, informed the Stock Exchanges that the ESOP Compensation Committee through resolutions passed on 20 August 2026, had approved grant of 4,15,060 Options at a grant price of Rs.2,371/- per option under the ESOP 2016 and 92,400 RSU under the RSU Plan 2021 to identified employee(s) of the Company. Subsequently, the ESOP Compensation Committee rescinded the aforesaid resolutions and cancelled the grant of the entire Options and RSUs granted vide resolutions passed on 20 August 2026. Accordingly, the grants of options and RSUs approved under those resolutions stand withdrawn and shall cease to have any force or effect.

2. Grant of 1,01,030 Options under the ESOP 2016 inter-alia on the following terms:

  • a) Grant Date :
  • b) Exercise Price :

7 September 2026

₹2, 371 per Option

  • c) Vesting Period :

5 years from the date of grant.

  • d) Vesting Proportion :

As mentioned in the resolution.

  • e) Exercise Period :

60 calendar months from the respective dates of vesting.

The Options granted are governed as per ESOP 2016 Plan, which was submitted with the Stock Exchanges at the time of obtaining in-principle approval and each of the Option entitles the holder to apply for one equity share of the Company of ₹10 each.

3. Grant of 22,510 RSUs under RSU Plan 2021 inter-alia on the following terms:

  • a) Grant Date :

7 September 2026

  • b) Exercise Price :
  • c) Vesting Period and Vesting Proportion :

₹10 per RSU

The RSUs shall vest in equal proportion over a period of four (4) years from the date of grant.

✓ verified by reading the document archived check · 2026-10-05 exchange filing →

Exchange Plaza, Plot No. C/1, G-Block, Bandra-Kurla Complex, Mumbai - 400 051

Scrip Symbol: MPHASIS

Initial

BG

Mphasis

TheNext Applied

  • RSU Grantees who have not opted for Automatic Exercise, the exercise period is 48 calendar months from the respective dates of vesting.

The RSUs granted are governed as per RSU Plan 2021, which was submitted with the Stock Exchanges at the time of obtaining in-principle approval and each of the RSUs entitles the holder to apply for one equity share of the Company of ₹10 each.

✓ verified by reading the document archived check · 2026-10-05 exchange filing →

MPHASIS: consolidated net profit changed by 10.8% in the quarter ending 30 June 2026, compared with the quarter ending 2025-06-30.

✓ verified by recomputing archived check · 2026-10-05 exchange filing →
Who holds it — from the filings
BCP TOPCO IX PTE. LTD. 30.5%KOTAK EMERGING EQUITY SCHEME (including other Kotak mutual funds consolidated based on PAN) 8.6%LIFE INSURANCE CORPORATION OF INDIA (including other LIC funds consolidated based on PAN) 6.9%HDFC MUTUAL FUND - HDFC MID-CAP OPPORTUNITIES FUND (including other HDFC mutual funds consolidated based on PAN) 6.1%ICICI PRUDENTIAL MUTUAL FUND (including other ICICI Prudential mutual funds consolidated based on PAN) 5.3%register as filed 2026-06-30
Filing timeline — what the company told the exchange

Follow this company without reading every document yourself.

Keep its available filings, dated fact checks and disclosure alerts together. Your saved country sets your market and its research schedule.

Start free — first week on us →
India ₹149/month · Rest of world US$4.99/month after the free trial · research, not investment advice · cancel any time
Or just the free morning: three facts checked against filings, every trading day, in your inbox.

Company data and archived claim checks are shown with available sources. Check the source and date before relying on a figure. This is not investment advice or a recommendation. Investment in securities markets is subject to market risks. Research on this site is produced with substantial use of AI. Terms, disclosures and grievances